Acelananumab has demonstrated satisfactory safety and tolerability in lowering Aβ plaques and delaying the clinical measure decrease in prodromal or mild AD patients. ARIA were the main safety observation. A dose-dependent adverse effect associated with the removal of Aβ, ARIA was more prevalent in ApoE ε4 carriers than in non-carriers. Here, APOE is linked to Alzheimer disease.